[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL150907A - Process for the preparation of stable amorphous calcium pseudomonate - Google Patents

Process for the preparation of stable amorphous calcium pseudomonate

Info

Publication number
IL150907A
IL150907A IL150907A IL15090702A IL150907A IL 150907 A IL150907 A IL 150907A IL 150907 A IL150907 A IL 150907A IL 15090702 A IL15090702 A IL 15090702A IL 150907 A IL150907 A IL 150907A
Authority
IL
Israel
Prior art keywords
pseudomonate
preparation
calcium pseudomonate
calcium
amorphous calcium
Prior art date
Application number
IL150907A
Other versions
IL150907A0 (en
Inventor
Stephan Cherkez
Joseph Kaspi
Alexander Weisman
Original Assignee
Stephan Cherkez
Joseph Kaspi
Chemagis Ltd
Alexander Weisman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stephan Cherkez, Joseph Kaspi, Chemagis Ltd, Alexander Weisman filed Critical Stephan Cherkez
Priority to IL150907A priority Critical patent/IL150907A/en
Publication of IL150907A0 publication Critical patent/IL150907A0/en
Priority to US10/439,389 priority patent/US20040039049A1/en
Priority to CA002429287A priority patent/CA2429287A1/en
Priority to JP2003170707A priority patent/JP2004059585A/en
Priority to EP03254626A priority patent/EP1384721A1/en
Priority to US11/028,292 priority patent/US20050159477A1/en
Publication of IL150907A publication Critical patent/IL150907A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

150,907/2 A PROCESS FOR THE PREPARATION OF STABLE AMORPHOUS CALCIUM PSEUDOMONATE , The present invention relates to a process for the preparation of a stable amorphous calcium pseudomonate, and to a stable amorphous calcium pseudomonate whenever prepared by said process.
Pseudomonic acid A (hereinafter referred to as pseudomonic acid) known also as mupirocin is isolated from fermentation broth of Pseudomonas Fluorescens. This compound is a highly potent antibiotic and it is used topically for treatment of bacterial infections. Bactroban® ointment, in which the active ingredient is pseudomonic acid, was introduced in the US market in 1987.
Patents GB 1 ,577,545 and GB 1 ,577,730 mention non-toxic salts of pseudomonic acid as candidates for administration. Among them is the calcium salt. No data regarding this material or processes for its preparation were given.
Several years later US 4,916,155, US 5,191 ,093 and US 5,436,266 describe calcium pseudomonate. These patents describe crystalline calcium pseudomonate as a dihydrate and as an anhydrous material. A process for the preparation of crystalline calcium pseudomonate is also given. It is used for the treatment of bacterial infections formulated as a nasal ointment and as a topical cream. A nasal ointment was introduced to the US market in 1995 and a topical cream in 1997. These patents also teach that while amorphous calcium pseudomonate is thermally labile, and decomposes on storage, the crystalline forms are stable and are suitable for use in pharmaceutical preparations. One of these patents (4,916,155) claims the crystalline anhydrous calcium pseudomonate, another (US 5,191 ,093) claims a process for the preparation of crystalline calcium pseudomonate both hydrous and anhydrous, while the third (5,436,266) claims crystalline hydrates (specifically the dihydrate) of calcium pseudomonate.
The recent discovery of the usefulness of amorphous calcium pseudomonate in topical preparations described in EP application 1 ,174,133 indicated the necessity of obtaining a stable amorphous calcium pseudomonate.
Amorphous calcium pseudomonate was described in US patents 4,916, 155, 5, 191 ,093 and US 5,436,266. A process for its preparation is also described. It is claimed there that the amorphous calcium salt is not thermally stable. Close examination of the data given in these patents shows that there are many questions left open. First, the inventors used a very low grade of pseudomonic acid and the calcium salts (crystalline and amorphous). Materials used had purity of 90-92% only. Mupirocin being a drug is controlled for its quality. Thus the British Pharmacopoeia states that mupirocin purity must be at least 93% pure. The same is required for the calcium salt. Measuring stability of impure material can lead to erroneous results. The behavior of pure material can be different from impure ones since in many instances the presence of high level of impurities can accelerate the decomposition of the product. Second, the decomposition of these materials was measured at very high temperatures (50°C and 80°C). Drugs are never stored at such high temperatures. Therefore, the decomposition rate at such temperatures is irrelevant. Third, at 37°C, all the compounds tested showed reasonable stability. Fourth, in all measurements amorphous calcium pseudomonate showed similar or better thermal stability compared with pseudomonic acid that is stable enough to be used as a drug.
Process for the preparation of amorphous calcium pseudomonate is described in US 4,916,155, US 5, 191 ,093 and US 5,436,266. A solution of pseudomonic acid is dissolved in a mixture of methanol and water and neutralized to pH 7.1 with calcium oxide. The solution is filtered and the solvents are evaporated under reduced pressure to give solid foam. Trituration of the foam with diethyl ether affords amorphous calcium pseudomonate.
This procedure is not applicable for a large-scale preparation. While handling a solid foam (that is usually rather sticky) is not a big problem in a laboratory scale of grams, it turns to be a huge, almost impossible task in large commercial scale. This process also uses diethyl ether in order to modify the foam obtained to a powder. Such an operation is also extremely difficult to carry out. Besides, this solvent is very inflammable and tends to make highly explosive mixtures with air. Therefore, its use in a large scale is a serious hazard.
When we tried to repeat the process as described in these patents we found out that besides the above-mentioned problems, an appreciable decomposition of the pseudomonate took place during the evaporation of the solvents. This decomposition occurred regardless of the conditions used to distill out the water.
Surprisingly it has now been found that lyophilization of a frozen solution of calcium pseudomonate afforded the amorphous calcium salt as a powdery material. The material also proved to be stable. It did not show decomposition when stored at an appropriate temperature.
More specifically, it has been found that neutralization of a suspension of pseudomonic acid in water with calcium hydroxide and lyophilization of the obtained solution results in a powder of amorphous calcium pseudomonate. The material thus obtained is stable and is suitable for use in pharmaceutical preparations (topical, nasal, otic, ophthalmic etc.).
Thus according to the present invention, there is now provided a process for the preparation of stable amorphous calcium pseudomonate comprising lyophilizing a frozen solution of calcium pseudomonate in water.
In preferred embodiments of the present invention said process is further characterized in that the solution of calcium pseudomonate in water is prepared by suspending pseudomonic acid in water and gradually adding calcium hydroxide to pH of 7.8-8.5, optionally filtering the solution from some insoluble material.
In especially preferred embodiments of the present invention the pH is maintained below 8.5 and the addition of calcium hydroxide is carried out at a temperature of below 15°C.
The invention also provides a stable pharmaceutical composition comprising amorphous calcium pseudomonate in a combination with a pharmaceutically acceptable carrier or excipient whenever prepared by the present process.
The following results illustrate findings according to the present invention: Table 1 : Stability results of pseudomonic acid amorphous Legend: P.A. = pseudomonic acid D.P. = decomposition product Samples thus prepared also remained amorphous during the storage period and did not show any evidence for spontaneous crystallization.
In addition, it has now been found that employing the process of the present invention results in no decomposition of the pseudomonic acid during the preparation of the calcium salt. Table 2 gives the results.
Table 2: Decomposition of pseudomonic acid during the process The calcium pseudomonate solution was prepared by a slow addition of solid calcium hydroxide to a suspension of pseudomonic acid in water. The calcium salt formed is gradually dissolved. The almost clear solution is filtered and frozen.
The use of calcium hydroxide is another feature of the invention. All the material used (pseudomonic acid, calcium hydroxide and water) are approved for use in human drugs. All the materials used have pharmacopoeial monographs. In this way the quality of the amorphous calcium pseudomonate is assured.
The safety (avoiding use of inflammable and explosive organic solvents) of the process and the ability to carry it out in a large commercial scale is still another feature of the invention.
While the invention will now be described in connection with certain preferred embodiments in the following examples so that aspects thereof may be more fully understood and appreciated, it is not intended to limit the invention to these particular embodiments. On the contrary, it is intended to cover all alternatives, modifications and equivalents as may be included within the scope of the invention as defined by the appended claims. Thus, the following examples which include preferred embodiments will serve to illustrate the practice of this invention, it being understood that the particulars shown are by way of example and for purposes of illustrative discussion of preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of formulation procedures as well as of the principles and conceptual aspects of the invention.
Example Pseudomonic acid (100 gjf.) is suspended in water (1000 ml). The mixture is cooled below 15°C and calcium hydroxide (ca. 7.0 c .) is added gradually until the pH is 8. The slightly turbid mixture is filtered and the solution is frozen and lyophilized. The product obtained is crushed and milled to give amorphous calcium pseudomonate in quantitative yield. The product was shown to be amorphous by XRD and IR analysis.
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative examples and that the present invention may be embodied in other specific forms without departing from the essential attributes thereof, and it is therefore desired that the present embodiments and examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

Claims (5)

7 150,907/2
1. A process for the preparation of stable amorphous calcium pseudomonate comprising lyophilizing a frozen solution of calcium pseudomonate in water.
2. A process for the preparation of stable amorphous calcium pseudomonate according to claim 1 further characterized that the solution of calcium pseudomonate in water is prepared by suspending pseudomonic acid in water and gradually adding calcium hydroxide to pH of 7.8-8.5 and optionally filtering the solution from some insoluble material.
3. A process according to claim 1 wherein the pH is maintained below 8.5.
4. A process according to claim 1 wherein the addition of calcium hydroxide is carried out a temperature below 15°C.
5. A stable amorphous calcium pseudomonate whenever prepared according to the process of claim 1. For the Applicant WOLFF, BREGMAN AND GOLLER by: / / 1 ·
IL150907A 2002-07-25 2002-07-25 Process for the preparation of stable amorphous calcium pseudomonate IL150907A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IL150907A IL150907A (en) 2002-07-25 2002-07-25 Process for the preparation of stable amorphous calcium pseudomonate
US10/439,389 US20040039049A1 (en) 2002-07-25 2003-05-15 Stable amorphous calcium pseudomonate and processes for the preparation thereof
CA002429287A CA2429287A1 (en) 2002-07-25 2003-05-21 Stable amorphous calcium pseudomonate and processes for the preparation thereof
JP2003170707A JP2004059585A (en) 2002-07-25 2003-06-16 Stable amorphous calcium pseudomonate and preparative method for the same
EP03254626A EP1384721A1 (en) 2002-07-25 2003-07-23 Stable amorphous calcium pseudomonate and processes for the preparation thereof
US11/028,292 US20050159477A1 (en) 2002-07-25 2005-01-03 Stable amorphous calcium pseudomonate and processes for the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL150907A IL150907A (en) 2002-07-25 2002-07-25 Process for the preparation of stable amorphous calcium pseudomonate

Publications (2)

Publication Number Publication Date
IL150907A0 IL150907A0 (en) 2003-02-12
IL150907A true IL150907A (en) 2007-07-04

Family

ID=29596365

Family Applications (1)

Application Number Title Priority Date Filing Date
IL150907A IL150907A (en) 2002-07-25 2002-07-25 Process for the preparation of stable amorphous calcium pseudomonate

Country Status (5)

Country Link
US (2) US20040039049A1 (en)
EP (1) EP1384721A1 (en)
JP (1) JP2004059585A (en)
CA (1) CA2429287A1 (en)
IL (1) IL150907A (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01007806A (en) * 1999-02-03 2003-06-04 Biogal Gyogyszergyar Process for the preparation of pseudomonic acid a antibiotic by microbiological method.
JP2005518780A (en) * 2001-06-21 2005-06-30 テバ ジョジセルジャール レースベニュタールシャシャーグ Metabolically controlled fermentation process for pseudomonic acid production
KR20040075857A (en) * 2001-12-28 2004-08-30 비오갈 기오기스제르갸르 알티. Processes for preparing crystalline and amorphous mupirocin calcium
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
WO2004018058A2 (en) * 2002-08-21 2004-03-04 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA06010084A (en) * 2004-06-01 2007-03-01 Teva Gyogyszergyar Zartkoruen Process for preparation of amorphous form of a drug.

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3977943A (en) * 1971-06-12 1976-08-31 Beecham Group Limited Antibiotics
US4071536A (en) * 1971-06-12 1978-01-31 Beecham Group Limited Antibiotics
US3758686A (en) * 1971-12-07 1973-09-11 American Cyanamid Co Method of using steroid acetonides
GB1532413A (en) * 1974-12-23 1978-11-15 Union International Co Ltd Chenodeoxycholic acid
US4206202A (en) * 1974-03-28 1980-06-03 Beecham Group Limited Antibiotics
US4146610A (en) * 1974-03-28 1979-03-27 Beecham Group Limited Antibiotics mm13902
US4113856A (en) * 1974-03-28 1978-09-12 Beecham Group Limited Antibiotic mm 13902
US4189473A (en) * 1974-03-28 1980-02-19 Beecham Group Limited Antibiotic MM 13902
US4205067A (en) * 1974-03-28 1980-05-27 Beecham Group Limited Antibiotics
IE41110B1 (en) * 1974-04-20 1979-10-24 Beecham Group Ltd Esters of clavulanic acid
NZ177159A (en) * 1974-04-20 1978-03-06 Beecham Group Ltd Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
GB1565083A (en) * 1976-02-20 1980-04-16 Beecham Group Ltd Pseudomonic acid amides
GB1587058A (en) * 1976-06-15 1981-03-25 Beecham Group Ltd Oxiranylmethyltetrahydropyran derivatives
US4206224A (en) * 1976-10-23 1980-06-03 Beecham Group Limited Treatment of infections
GB1577730A (en) * 1976-10-23 1980-10-29 Beecham Group Ltd Treatment of infections with pseudomonicacid salts or esters thereof
GB1577931A (en) * 1977-02-11 1980-10-29 Beecham Group Ltd 6-methoxy -6-(2-carboxy-2-(4-hydroxyphenyl) acetamido penicillins
GB1577545A (en) * 1977-07-27 1980-10-22 Beecham Group Ltd Treatment of swine dysenter
CA1103264A (en) * 1977-09-30 1981-06-16 Norman H. Rogers Purification of pseudomonic acid
EP0003069B1 (en) * 1977-11-01 1981-05-20 Beecham Group Plc Pseudomonic acid c, pharmaceutically acceptable salts or esters thereof, processes for their preparation and pharmaceutical or veterinary compositions containing them
DE2860726D1 (en) * 1977-11-05 1981-08-27 Beecham Group Plc Antibacterially active amides, process for their preparation and pharmaceutical compositions containing said amides
IL56003A0 (en) * 1977-12-03 1979-01-31 Beecham Group Ltd Novel thiol esters of monic acid, their preparation and pharmaceutical compositions containing them
CA1115699A (en) * 1978-05-20 1982-01-05 Alan D. Curzons Lithium pseudomonate and its preparation
ZA802446B (en) * 1979-05-15 1981-04-29 Beecham Group Ltd Process for the preparation of penicillin derivatives
DE3066411D1 (en) * 1979-09-28 1984-03-08 Beecham Group Plc Antibacterial sulphonamides, processes for their preparation and compositions containing them
DE3066424D1 (en) * 1979-11-10 1984-03-08 Beecham Group Plc Antibacterial derivatives of monic acid, processes for their preparation and compositions containing them
EP0042233A1 (en) * 1980-06-14 1981-12-23 Beecham Group Plc 13-oxo-monic acid and its salts and esters, process for their production, and compositions containing them
EP0044801B1 (en) * 1980-07-17 1984-02-15 Josef Dr. Klosa Non hygroscopic salts of 4-hydroxy-butanoic acid, process for their preparation and their use for the manufacture of pharmaceutic agents
EP0045150A1 (en) * 1980-07-24 1982-02-03 Beecham Group Plc Antibacterial compounds, processes for their preparation and composititions containing them
US4436751A (en) * 1980-12-31 1984-03-13 Beecham Group Limited Nitrobenzyl monates antibacterial compounds
EP0081325A3 (en) * 1981-12-09 1984-05-23 Beecham Group Plc Antibacterial compounds
AU563067B2 (en) * 1982-02-27 1987-06-25 Beecham Group Plc Heterocyclic normonyl derivatives
CA1196284A (en) * 1982-05-28 1985-11-05 Joshua Oduro-Yeboah Pharmaceutical formulations
GB8401965D0 (en) * 1984-01-25 1984-02-29 Beecham Group Plc Composition
US4940701A (en) * 1984-01-25 1990-07-10 Beecham Group P.L.C. Topical drug release system
GB8415579D0 (en) * 1984-06-19 1984-07-25 Beecham Group Plc Compounds
US4892960A (en) * 1985-01-28 1990-01-09 International Minerals & Chemical Corp. Crystalline lysocellin compositions and method of making
US4847068A (en) * 1987-08-06 1989-07-11 Johnson & Johnson Consumer Products, Inc. Skin care compositions
IL95952A0 (en) * 1989-10-19 1991-07-18 Sterling Drug Inc Aerosol composition for topical medicament
US5714165A (en) * 1990-09-20 1998-02-03 Mikkur, Inc. Bioadhesive polyethylene glycol ointment for medicaments
US5594026A (en) * 1990-12-11 1997-01-14 Smithkline Beecham Group P.L.C. Polymorphs of crystalline mupirocin
US5230703A (en) * 1992-04-09 1993-07-27 Staodyn, Inc. Wound infection resolution utilizing antibiotic agents and electrical stimulation
GB9313796D0 (en) * 1993-07-03 1993-08-18 Smithkline Beecham Plc Novel bioprocess
AU692486B2 (en) * 1993-10-22 1998-06-11 Smithkline Beecham Corporation Pharmaceutical or veterinary composition comprising mupirocin or a salt thereof in a cream base
US5786376A (en) * 1994-07-23 1998-07-28 Smithkline Beecham Corporation Methods of treating opportunistic infections with azaspiranes
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
GB9424562D0 (en) * 1994-12-06 1995-01-25 Giltech Ltd Product
US6057291A (en) * 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
US5744151A (en) * 1995-06-30 1998-04-28 Capelli; Christopher C. Silver-based pharmaceutical compositions
GB9616208D0 (en) * 1996-08-01 1996-09-11 Smithkline Beecham Plc Novel Compounds
US6093414A (en) * 1997-08-11 2000-07-25 Christopher C. Capelli Silver-based antimicrobial compositions
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
CO4910145A1 (en) * 1996-10-01 2000-04-24 Smithkline Beecham Corp USE
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US6413496B1 (en) * 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US7067500B2 (en) * 1997-05-02 2006-06-27 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6406880B1 (en) * 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US20010044584A1 (en) * 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
US6486214B1 (en) * 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
IL123143A (en) * 1998-02-02 2001-08-26 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
US6231875B1 (en) * 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
TR200002965T2 (en) * 1998-04-14 2001-05-21 Jomaa,Hassan The use of organophosphorus preparations for the therapeutic and prophylactic treatment of infections
BR9912062A (en) * 1998-07-15 2001-04-03 Hassan Jomaa Phosphorous organic compounds and their use
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
MXPA01007806A (en) * 1999-02-03 2003-06-04 Biogal Gyogyszergyar Process for the preparation of pseudomonic acid a antibiotic by microbiological method.
TR200102232T2 (en) * 1999-02-03 2002-02-21 Biogal Gyogyszergyar Rt. The process for isolating pseudomonic acid A from the culture medium containing pseudomonic acid complex.
US6335023B1 (en) * 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6265181B1 (en) * 1999-09-24 2001-07-24 The Public Health Research Institute Of The City Of New York, Inc. Dosing and development of antimicrobial and antiviral drugs determined by restriction of resistant mutant selection
US6528086B2 (en) * 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
IL150224A0 (en) * 1999-12-15 2002-12-01 Cubist Pharm Inc Lipopeptides and pharmaceutical compositions containing the same
CN1425025A (en) * 1999-12-15 2003-06-18 卡比斯特制药公司 Daptomycin analogs as antibacterial agents
AU780247B2 (en) * 1999-12-17 2005-03-10 Pfizer Science And Technology Ireland Limited A process for producing crystalline atorvastatin calcium
DE10032017A1 (en) * 2000-07-01 2002-01-10 Clariant Gmbh Process for the production of high-purity formylphenylboronic acids
US6375982B1 (en) * 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
IL137363A (en) * 2000-07-18 2005-12-18 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
EP1309354A2 (en) * 2000-07-27 2003-05-14 Rutgers, The State University Therapeutic polyesters and polyamides
US20020091074A1 (en) * 2000-09-20 2002-07-11 Wooley Richard E. Medical compositions, dressings and methods for treating microbial infections of skin lesions
US6518252B2 (en) * 2000-09-20 2003-02-11 University Of Georgia Research Foundation, Inc. Method of treating aquatic animals with an antimicrobial agent and chelating agent
US20030008844A1 (en) * 2001-05-17 2003-01-09 Keryx Biopharmaceuticals, Inc. Use of sulodexide for the treatment of inflammatory bowel disease
US6689893B2 (en) * 2001-05-18 2004-02-10 Omg Americas, Inc. Shelf stable haze free liquids of overbased alkaline earth metal salts
US6680797B2 (en) * 2001-06-21 2004-01-20 The United States Of America As Represented By The National Aeronautics And Space Administration Spatial light modulators for full cross-connections in optical networks
JP2005518780A (en) * 2001-06-21 2005-06-30 テバ ジョジセルジャール レースベニュタールシャシャーグ Metabolically controlled fermentation process for pseudomonic acid production
WO2003028646A2 (en) * 2001-10-01 2003-04-10 The Board Of Trustees Of The University Of Illinois Methods of treating drug-resistant bacterial infections
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US6696971B2 (en) * 2001-12-12 2004-02-24 Gess Tukin Audible combination light socket-adapter
KR20040075857A (en) * 2001-12-28 2004-08-30 비오갈 기오기스제르갸르 알티. Processes for preparing crystalline and amorphous mupirocin calcium
WO2004006832A2 (en) * 2002-05-13 2004-01-22 Tony Romeo Methods and compounds for reducing biofilm formation
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
US20040076671A1 (en) * 2002-10-21 2004-04-22 Aletha Tippett Methods and compositions for topical wound treatment

Also Published As

Publication number Publication date
JP2004059585A (en) 2004-02-26
CA2429287A1 (en) 2004-01-25
US20050159477A1 (en) 2005-07-21
IL150907A0 (en) 2003-02-12
US20040039049A1 (en) 2004-02-26
EP1384721A1 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
KR100744917B1 (en) A Novel Crystalline Form of N-[4-[2-2-Amino-4,7-Dihydro-4-Oxo-3H-Pyrrolo[2,3-d]Pyrimidin-5-ylEthyl]Benzoyl]-L-Glutamic Acid and Process Therefor
US6486149B2 (en) Composition comprising a crystallographically stable, amorphous cephalosporin and processes for the preparation thereof
CA1187484A (en) Crystalline benzenesulfonate salts of sultamicillin
ES2622356T3 (en) Crystalline forms of tigecycline and processes for its preparation
KR840001776B1 (en) Process for preparing seftazidime pentahydrate
CA1109795A (en) Compositions comprising a cephalosporin and a carbonic acid salt
KR101626506B1 (en) Hydrates of erythromycin salts, the preparation and the use thereof
CN102180890B (en) Cefathiamidine hydrate and preparation method and application thereof
CN105121409B (en) Crystalline form of dolutegravir sodium salt and preparation method therefor
US20050159477A1 (en) Stable amorphous calcium pseudomonate and processes for the preparation thereof
WO2021227146A1 (en) N-[8-(2-hydroxybenzoyl)amino]monopotassium octanoate crystal compound, and preparation method therefor and use thereof
JP2568226B2 (en) Lyophilized or precipitated cephalosporins zwitterions and salt conjugates
KR100195882B1 (en) Novel crystal of cephalosporin compound
CA3189271A1 (en) A precipitation process for amorphous letermovir
CN102212074A (en) Cefonicid sodium hydrate and preparation method and application thereof
US4222939A (en) Process for preparing solid sodium amoxycillin
EP0006223A1 (en) Crystalline sodium and potassium indomethacin and their trihydrates, process for preparing and pharmaceutical compositions containing the same
AU4867799A (en) Injectable sodium acetylsalicylate composition and method
CN102424688B (en) Levoulifloxacin mesylate crystal, its preparation method and application
JPWO2019151133A1 (en) Method for producing bortezomib crystals
US20210283213A1 (en) Crystal of polymyxin b1 sulfate, polymyxin b2 sulfate or their mixture and preparation method thereof
MXPA05010083A (en) Cephalosporin in crystalline form.
EP2230240A1 (en) Stable crystal of -lactam compound
MXPA96006325A (en) New variante cristalina del cdch, procedure for its production and pharmaceutical preparations that contains it

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees